The PSMA PET based radiomics to characterize PCa aggressiveness on histopathology and whole-body scanning has the potential to make PSMA PET/CT a one-stop shop for individualized PCa management and prognosis assessment. The gene discussed is FOLH1; the disease is posterior cortical atrophy.